Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Apellis Pharmaceuticals (APLS) Gross Profit (2021 - 2025)

Apellis Pharmaceuticals (APLS) has 5 years of Gross Profit data on record, last reported at $170.2 million in Q4 2025.

  • For Q4 2025, Gross Profit fell 0.86% year-over-year to $170.2 million; the TTM value through Dec 2025 reached $901.5 million, up 35.85%, while the annual FY2025 figure was $901.5 million, 35.85% up from the prior year.
  • Gross Profit reached $170.2 million in Q4 2025 per APLS's latest filing, down from $434.0 million in the prior quarter.
  • Across five years, Gross Profit topped out at $434.0 million in Q3 2025 and bottomed at $5.5 million in Q3 2021.
  • Average Gross Profit over 5 years is $113.3 million, with a median of $107.2 million recorded in 2023.
  • Peak YoY movement for Gross Profit: tumbled 67.23% in 2022, then skyrocketed 540.72% in 2023.
  • A 5-year view of Gross Profit shows it stood at $60.2 million in 2021, then crashed by 67.23% to $19.7 million in 2022, then surged by 540.72% to $126.5 million in 2023, then skyrocketed by 35.75% to $171.7 million in 2024, then decreased by 0.86% to $170.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Gross Profit were $170.2 million in Q4 2025, $434.0 million in Q3 2025, and $164.9 million in Q2 2025.